Indian study finds 1st evidence on how nanoplastics from single-use PET bottles harm body

PIB Photo

New Delhi, (IANS): Nanoplastics derived from single-use PET bottles can directly disrupt key biological systems that are vital for human health, according to a study led by the Institute of Nano Science and Technology, Mohali (INST), an autonomous institute of the Department of Science and Technology (DST), on Thursday.

Nanoplastics, found in food and water, are a global concern and are increasingly being detected inside the human body. But their exact effects remain poorly understood.

While many studies had focused on how plastics pollute the environment or damage host tissues, almost nothing was known about their direct impact on beneficial gut microbes that are central to human health.

The team led by Prashant Sharma and Sakshi Dagariya from the Chemical Biology Unit at INST found the first clear evidence of profound consequences to human health.

The researchers found that long-term exposure reduced bacterial growth, colonisation, and protective functions, while increasing stress responses and sensitivity to antibiotics.

"Together, the findings explain that nano-plastics from everyday plastics are biologically active particles that can interfere with gut health, blood stability, and cellular function," said the researchers in the paper published in the journal Nanoscale Advances.

The team recreated Nano-plastics from PET bottles in the laboratory and tested them across three key biological models.

A beneficial gut bacterium, Lactobacillus rhamnosus, was used to see how nanoplastics affect the microbiome.

At higher concentrations, nanoplastics were found to disrupt red blood cell membranes and cause premature destruction of the cells.

Further, the team also found that prolonged exposure led to DNA damage, oxidative stress, apoptosis, and inflammatory signalling, alongside shifts in energy and nutrient metabolism.

"The nanoparticles induce DNA damage, oxidative stress, and inflammatory responses in human epithelial cells during prolonged exposure, posing risks to human health that were previously unrecognised," the researchers said.Beyond human health, the insights can extend to agriculture, nutrition, and ecosystem studies, where microbial balance and plastic pollution intersect, they noted. Indian study finds 1st evidence on how nanoplastics from single-use PET bottles harm body | MorungExpress | morungexpress.com
Read More........

Scorpion Venom May Provide the Next Breast Cancer Breakthrough

– credit Marino Linic

Scientists in Brazil are currently testing to see if the venom of an Amazonian scorpion could be used to poison breast cancer tumors.

Researchers at the University of São Paulo’s Preto School of Pharmaceutical Sciences (FCFRP-USP) have long worked to clone and express proteins from rattlesnake and scorpion venom with hopes of transforming these powerful compounds into medicines.

Recently, their work identified that venom of the scorpion Brotheas amazonicus appears to attack breast cancer cells in a way similar to a widely used chemotherapy medication.

These early findings were generated through a collaboration with scientists from the National Institute for Amazonian Research (INPA) and the Amazonas State University (UEA).

“Through bioprospecting, we were able to identify a molecule in the species of this Amazonian scorpion that is similar to that found in the venoms of other scorpions and that acts against breast cancer cells,” said Eliane Candiani Arantes, a professor at FCFRP-USP and the coordinator of the project.

Arantes and her team identified two neurotoxins in scorpion venom with immunosuppressive effects. Working with collaborators at INPA and UEA, they found a peptide named BamazScplp1 in the venom of Brotheas amazonicus that appears to have anti-tumor potential.

Laboratory tests showed that the peptide’s impact on breast cancer cells was comparable to paclitaxel, a commonly prescribed chemotherapy treatment. It primarily triggers necrosis, a form of cell death previously associated with molecules from other scorpion species.

Arantes and her team have isolated other components of venoms from scorpions and from snakes that have been used to help develop other clinical applications, including an internal wound sealant that mimics the body’s natural clotting and scaffolding processes. It’s undergoing trials for use in nerve repair, bone healing, and restoring movement following spinal cord injury.Next time you see a scorpion, and think it a nasty creepy crawly that will send you to the hospital, show a bit of grace; they might help save a woman’s life some day. Scorpion Venom May Provide the Next Breast Cancer Breakthrough
Read More........

Indian scientists find genetic clues to tackle oral cancer among women

Photo: https://www.nibmg.ac.in)

New Delhi, (IANS) A team of Indian scientists has discovered oral cancer-causing driver gene mutations in women patients in southern parts of the country.

The team from the Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR), Bengaluru and the BRIC-National Institute of Biomedical Genomics (NIBMG), Kalyani, in collaboration with clinicians from Sri Devraj Urs Academy of Higher Education and Research (SDUAHER), Kolar, conducted a female-centric study on oral cancer in India with a unique tobacco chewing habit.

This study led by Professor Tapas K Kundu, JNCASR, Bengaluru aimed to understand what makes cancers in women unique, how the disease manifests and progresses in female patients and how we can treat them better.

The team also used artificial intelligence (deep learning) to digitally analyse tumour tissues. This revealed two distinct groups of female patients, each with a different immune response in their tumours.

India carries one of the world’s heaviest burdens of oral cancer with alarmingly high rates witnessed among women in certain regions, especially in southern and northeast India, due to the widespread habit of chewing tobacco-infused betel quid, gutka, and related products.

While the disease is widely studied in men, oral cancer in women has often remained under the radar.

The study was performed on paired tumour and blood samples from female OSCC-GB patients with a unique regional tobacco-chewing habit (Kaddipudi), commonly observed among women in the Kolar district of Karnataka.

Analysis of this women-centric cohort has revealed a unique driver mutation implicated in oral tumorigenesis.

This investigation, published in the Clinical and Translational Medicine Journal, was specifically designed to uncover the biological underpinnings of the disproportionately aggressive, highly recurrent, and life-threatening forms of oral cancer that affect Indian women.

Using cutting-edge whole-exome sequencing, the researchers identified ten key genes with significant mutations in the female oral cancer cohort from Kolar, Karnataka.

Although two of the major genes, CASP8 and TP53, were found to be highly mutated in these patients, uniquely, CASP8 seems to be the driver mutation (cancer-causing), which is quite different compared to previously studied mutations in oral cancer patients (largely men).

The findings suggest that co-occurring TP53 and CASP8 mutations confer a markedly aggressive and lethal phenotype in oral cancer.The team is now focused on delineating the molecular mechanisms of oncogenesis driven by this novel driver mutation within the background of TP53 alterations for the next phase of the research. Indian scientists find genetic clues to tackle oral cancer among women | MorungExpress | morungexpress.com
Read More........

Australia leads first human trial of one-time gene editing therapy to halve bad cholesterol


IANS Photo

Melbourne, November 10 (IANS): Researchers in Australia have led a first-in-human trial for a breakthrough gene-editing therapy that halves bad cholesterol and triglycerides in people with difficult-to-treat lipid disorders.

The trial tested CTX310, a one-time CRISPR-Cas9 gene-editing therapy that uses fat-based particles to carry CRISPR editing tools into the liver, switching off the ANGPTL3 gene. Turning off this gene lowers LDL (bad) cholesterol and triglycerides, two blood fats linked to heart disease, according to a statement released Monday by Australia's Monash University.

The Victorian Heart Hospital, operated by Monash Health in partnership with Monash University, treated three of 15 patients aged 18-75 years with difficult-to-treat lipid disorders in phase 1 of the global trial conducted across Australia, New Zealand, and Britain, the statement said, Xinhua news agency reported.

At the highest dose, a single-course treatment with CTX310 resulted in a mean reduction of LDL cholesterol by 50 per cent and triglycerides by 55 per cent, remaining low for at least 60 days after two weeks of treatment, it said, adding LDL cholesterol and triglycerides were reduced by nearly 60 per cent among all participants with various doses, with only mild, short-term side effects reported.

Importantly, CTX310 is the first therapy to achieve large reductions in both LDL cholesterol and triglycerides at the same time, marking a potential breakthrough for people with mixed lipid disorders who have elevations in both, according to the trial published in the New England Journal of Medicine.

"The possibility of a single-course treatment with lasting effects could be a major step in how we prevent heart disease," said Stephen Nicholls, Director of the Victorian Heart Hospital, and study lead investigator."It makes treatment easier, reduces ongoing costs, relieves pressure on the health system, all while improving a person's quality of life," Nicholls said, emphasising plans to focus on larger and more diverse patient populations in future trials of CTX310. Australia leads first human trial of one-time gene editing therapy to halve bad cholesterol | MorungExpress | morungexpress.com
Read More........

Boy with Rare Genetic Disorder Amazes Doctors After World-First Gene Therapy

Courtesy of Oliver Chu family

The first child in history has successfully been treated with a new genetic therapy for an ultra-rare developmental defect called Hunter syndrome.

Several years in the making, Oliver Chu became the first in the world to receive the stem cell-based treatment in February, and 3 months later seemed to be a normal child again, meeting important milestones and playing without supervision.

Royal Manchester Children’s Hospital, which oversaw the trial of Oliver and 4 other patients, says that children with severe Hunter syndrome cannot properly break down complex sugar molecules and have widespread symptoms including rapid and progressive learning and memory problems, heart and lung dysfunction, hyperactivity and behavioral problems, bone and joint malformations and hearing impairment.

They cannot break down the sugars because their genetic code was formed with a defect: the gene that codes for the production of an enzyme called iduronate-2-sulfatase (IDS) doesn’t work properly.

Professor Brian Pigger, professor of cell and gene therapy at the University of Manchester, developed a method of replacing the faulty gene with a functioning copy, called autologous hematopoietic stem cell (HSC) gene therapy.

In December, Oliver Chu, from California, arrived at Royal Manchester for the first stage of the procedure. The 3-year-old had his blood cycled in a machine to extract the hematopoietic stem cells he produces naturally. These were then sent off to a laboratory at Great Ormond Street Hospital in London, where a functioning copy of the defective gene is inserted into a virus and placed inside the stem cells.

In February, mother Jingru cradled Oliver in his hospital bed as he received an injection of 125 million modified cells twice in the space of 2 hours. It was a momentous day that the young boy was completely oblivious to.

After a few days, Oliver flew back to California to reunite with his older brother Skyler, who also has the disease, and his father Ricky.

Hunter syndrome affects almost exclusively boys, and then only 1 in 100,000 live births. A major challenge in the disease that can often be fatal is that treatment methods can’t cross the blood-brain barrier, as the major manifestation of the inability to break down sugars occurs in the brain.

One commercially available drug called Elaprase can slow the effects, but can’t cross the blood brain barrier. It costs as much as a house for a year’s prescription. Another treatment has been to give regular infusions of the missing enzyme, just like a diabetic would take infusions of insulin.

In May of this year, BBC reports that Oliver’s development has become remarkably normal. He’s talking all the time, and been able to stop the enzyme infusions. He runs around like any other 3-year-old, utilizing a newly-exploded vocabulary, and demonstrates genuine inquisitiveness.

“Every time we talk about it I want to cry because it’s just so amazing,” his mother Jingru told the BBC.

“We can see he’s improving, he’s learning, he’s got new words and new skills and he’s moving around much more easily,” said Professor Simon Jones, who ran the trial that saw Oliver and four other boys receive the gene therapy. “We need to be careful and not get carried away in the excitement of all this, but things are as good as they could be at this point in time.”

Unfortunately for Skyler, who also has Hunter syndrome, he’s too old to receive his younger brother’s treatment. The 5-year-old receives infusions like Oliver used to, it allows him to regain some physical development normalcy, but the infusions can’t cross the blood-brain barrier.The treatment window in the trial was 3 months to 1 year of age. It was originally believed that Oliver was too old, but a battery of tests concluded there was still a window where the therapy might reverse the genetic defect in the brain as well as the body. Ricky is hopeful the treatment will prove successful, prompting further innovation into how it might help treat older children like Skyler. Boy with Rare Genetic Disorder Amazes Doctors After World-First Gene Therapy
Read More........

Parkinson's disease causes progressive changes in brain's blood vessels: Study

IANS Photo

New Delhi, (IANS): Researchers in Australia have found that Parkinson's disease causes significant and progressive changes in the brain's blood vessels, changing the understanding of the disease.

While Parkinson's disease is characterised by alpha-synuclein protein deposits, the research demonstrated that region-specific changes to blood vessels in the brain underlie disease progression, Xinhua news agency reported.

"Traditionally, Parkinson's researchers have focused on protein accumulation and neuronal loss, but we have shown the impacts on our cerebrovasculature -- the blood vessels in our brain," said Derya Dik, postdoctoral student at Neuroscience Research Australia (NeuRA).

"Our research identified region-specific changes in the brain's blood vessels, including an increased presence of string vessels, which are non-functional remnants of capillaries," Dik added.

NeuRA researchers, in collaboration with the University of New South Wales and the University of Sydney, also observed changes relating to how blood flows in the brain and how the blood-brain barrier operates.

The findings, published in the journal Brain, may also help open up new treatment avenues.

Researchers believe that targeting these progressive, region-specific changes may be able to slow disease progression and improve outcomes for patients suffering from Parkinson's disease.

In addition to exploring what these findings mean for people with Parkinson's disease, the researchers are considering impacts for other neurodegenerative disorders.

"We are now investigating whether similar cerebrovascular changes are present in post-mortem brain tissue from individuals with Alzheimer's disease and dementia with Lewy bodies tissue," Dik said."This study may lead to new treatment options for people with Parkinson's disease, but we also want to better understand the contribution of vascular pathology in these other neurodegenerative disorders and explore whether this can reveal new targets for therapies and treatments for people with those conditions also," the researcher said. Parkinson's disease causes progressive changes in brain's blood vessels: Study | MorungExpress | morungexpress.com
Read More........

Japanese researchers successfully regenerate bone using stem cells


IANS Photo

New Delhi, (IANS): A team of researchers from Japan has successfully treated spinal fractures in animal models using stem cells from fatty tissue.

The team from the Osaka Metropolitan University used stem cells extracted from adipose -- the body’s fatty tissue -- to treat spine fractures in rats similar to those caused by osteoporosis in humans.

These cells offer the advantages of being easy to collect, even from elderly individuals, and causing little stress to the body, suggesting a non-invasive way of treating bone diseases.

Bone regeneration and strength were significantly improved in rats transplanted with the adipose tissue (ADSCs).

The genes involved in bone formation and regeneration were also activated. The study was published in Bone and Joint Research.

“This study has revealed the potential of bone differentiation spheroids using ADSCs for the development of new treatments for spinal fractures,” said Yuta Sawada, a student at the varsity's Graduate School of Medicine.

“Since the cells are obtained from fat, there is little burden on the body, ensuring patient safety. This simple and effective method can treat even difficult fractures and may accelerate healing,” added Dr. Shinji Takahashi.

Osteoporosis is a disease that causes bones to become brittle and prone to fractures. Among osteoporosis-related fractures, compression fractures of the spine -- known as osteoporotic vertebral fractures -- are the most common type of fracture and pose a serious problem, leading to a need for long-term care and a significant decline in quality of life.

The team used stem cells, which are multipotent, meaning that they can be differentiated into many different cell types.

They developed ADSCs into bone-differentiated spheroids -- three-dimensional spherical clusters -- and combined it with beta-tricalcium phosphate, a material widely used for bone reconstruction, to successfully treat rats with spinal fractures.“This technique is expected to become a new treatment that helps extend the healthy life of patients,” Takahashi said. Japanese researchers successfully regenerate bone using stem cells | MorungExpress | morungexpress.com
Read More........

Unique Antibody from Camels and Alpacas Could Be Used to Treat Alzheimer’s

credit, Sung Jin Cho on Unsplash

An antibody-like compound known on land to be exclusively to be found in camelids like alpacas, lamas, and dromedaries, could be used to treat human brain disorders such as Alzheimer’s disease, according to a new study.

The study’s focus were antibody-like proteins, aptly called nanobodies, whose small size allowed the scientists to treat neurological conditions in mice more effectively and with fewer side effects.

The study, published in the journal Trends in Pharmacological Sciences, outlines the next steps towards developing nanobody treatments that are safe for humans.

“Camelid nanobodies open a new era of biologic therapies for brain disorders and revolutionize our thinking about therapeutics,” said Dr. Philippe Rondard, of Centre National de la Recherche Scientifique (CNRS) in France.

“We believe they can form a new class of drugs between conventional antibodies and small molecules.”

Nanobodies were first discovered in the early 1990s by Belgian scientists studying the immune systems of camelids. They found that as well as making conventional antibodies, which are composed of two heavy chains and two light chains, camelids also produce antibodies with just heavy chains.

The antigen-binding fragments of those antibodies are now known as nanobodies. They’re just one-tenth the size of conventional antibodies, and have not been found in any other mammals, say scientists, although they have been observed recently in some cartilaginous fish.

Therapeutic approaches for diseases such as cancer and autoimmune disorders often centre around antibodies. The treatments that have shown some therapeutic benefits, including a few drugs for Alzheimer’s treatment, are often associated with secondary side effects, however.

With their much smaller size, scientists say nanobodies have the potential to offer better efficacy for brain diseases with fewer side effects. In previous studies, the team has shown that nanobodies can restore behavioral deficits in mouse models of schizophrenia and other neurologic conditions.

“These are highly soluble small proteins that can enter the brain passively,” said co-author Dr. Pierre-André Lafon, also of CNRS. “By contrast, small-molecule drugs that are designed to cross the blood-brain barrier are hydrophobic in nature, which limits their bioavailability, increases the risk of off-target binding, and is linked to side effects.”

He says nanobodies are also easier than conventional antibodies to produce, purify, and engineer and can be fine-tuned to their targets.

But the researchers acknowledge that several steps need to be taken before nanobodies can be tested in human clinical trials for brain disorders. They say toxicology and long-term safety testing are essential, and the effect of chronic administration needs to be understood.

“It will be necessary to obtain clinical-grade nanobodies and stable formulations that maintain activity during long-term storage and transport,” said Dr. Rondard.Dr Lafon added that his lab has already started to study these different parameters for a few brain-penetrant nanobodies and has recently shown that conditions of treatment are compatible with chronic treatment.” Unique Antibody from Camels and Alpacas Could Be Used to Treat Alzheimer’s
Read More........

New online tool to transform how high blood pressure is treated

IANS Photo

New Delhi, (IANS): A global team of researchers from India, Australia, the US, and the UK has developed a novel online-based tool which can transform how hypertension is managed, allowing doctors to choose a treatment for each patient based on the degree to which they need to lower their blood pressure.

The 'blood pressure treatment efficacy calculator' is built on data from nearly 500 randomised clinical trials in over 100,000 people. It allows doctors to see how different medications are likely to lower blood pressure.

“We cannot overlook the importance of controlling high blood pressure effectively and efficiently. Achieving optimal control requires a clear understanding of the efficacy of antihypertensive drugs at different doses and in various combinations. Without clarity on what we want to achieve and how to achieve it, we will not meet our targets. Guidelines define the target blood pressure, while our online tool helps identify which antihypertensive drugs are best suited to reach that target,” said Dr. Mohammad Abdul Salam, from The George Institute for Global Health, Hyderabad.

A single antihypertensive medication -- still the most common way treatment is started -- typically lowers systolic BP by just 8-9 mmHg, while most patients need reductions of 15-30 mmHg to reach ideal targets.

Nelson Wang, cardiologist and Research Fellow at the Institute, noted that while the traditional way of doing this is by measuring blood pressure directly for each patient and adjusting treatment accordingly, BP readings are far too variable, or ‘noisy’, for it to be reliable.

The new tool, described in research published in The Lancet, helps overcome this challenge by calculating the average treatment effect seen across hundreds of trials.

It also categorises treatments as low, moderate, and high intensity, based on how much they lower blood pressure (BP) -- an approach already routinely used in cholesterol-lowering treatment.

High blood pressure is one of the world’s biggest health challenges, affecting as many as 1.3 billion people and leading to around ten million deaths each year.Often called a silent killer as it does not cause any symptoms on its own, it can remain hidden until it leads to a heart attack, stroke, or kidney disease. Fewer than one in five people with hypertension have it under control. New online tool to transform how high blood pressure is treated | MorungExpress | morungexpress.com
Read More........

Nagaland University researchers find plant compound to treat diabetic wound, foot ulcers


IANS Photo

New Delhi, (IANS): Researchers at the Nagaland University have identified a naturally occurring plant compound called ‘Sinapic acid’ as a powerful therapeutic agent that can significantly enable wound healing in patients with diabetes.

A diabetic wound is a slow-healing sore, most often a foot ulcer. Also known as diabetic foot, it raises the risk of nerve damage (neuropathy) and poor blood circulation, foot ulcers, infections, and amputation in severe cases.

The study, published in the journal Nature Scientific Reports, demonstrated that oral administration of Sinapic acid can accelerate diabetic wound healing in preclinical models.

Sinapic acid is a naturally occurring antioxidant found in various edible plants.

The research established that the compound works by activating the SIRT1 pathway, which plays a crucial role in tissue repair, angiogenesis, and inflammation control.

The discovery marks a major advancement that could result in safe, natural, and effective treatments for diabetic wound management.

“Diabetes mellitus remains one of the world’s most pressing chronic diseases, affecting hundreds of millions globally. Among its serious complications is delayed wound healing, often resulting in diabetic foot ulcers, infection, and, in severe cases, amputation. Existing synthetic drugs have shown limited efficacy and often cause undesirable side effects,” said Prof. Pranav Kumar Prabhakar, Head, Department of Biotechnology, School of Engineering and Technology, Nagaland University.

“We found that a lower dose (20 mg/kg) was more effective than a higher one (40 mg/kg), a phenomenon known as ‘Inverted Dose-Response.’ This result not only optimises dosage strategy but also has significant clinical implications for future drug development,” he added.

Importantly, the discovery will help reduce the risk of amputation and accelerate recovery in diabetic foot ulcers and providing an affordable, natural oral therapy, improving accessibility for patients in rural and resource-limited settings.The research developed robust preclinical evidence that Sinapic acid enhances wound healing, improves metabolic health, and mitigates oxidative stress in diabetic models. The next phase includes pilot clinical trials, said the researchers. Nagaland University researchers find plant compound to treat diabetic wound, foot ulcers | MorungExpress | morungexpress.com
Read More........

Study shows eye scans may provide clues to ageing, heart disease risk

(Photo: AI generated image/IANS)

New Delhi, (IANS) Canadian researchers have found that scanning the tiny blood vessels in the eyes may help predict a person's risk of developing heart disease and how fast they're biologically ageing.

The study, published in the journal Science Advances, suggests that retinal scans could one day serve as a noninvasive window into the body's overall vascular health and biological ageing status, offering new opportunities for early detection and intervention.

"By connecting retinal scans, genetics, and blood biomarkers, we have uncovered molecular pathways that help explain how aging affects the vascular system," said Marie Pigeyre, Associate Professor at McMaster University’s Department of Medicine in Canada.

"The eye provides a unique, noninvasive view into the body's circulatory system. Changes in the retinal blood vessels often mirror changes occurring throughout the body's small vessels," added Pigeyre.

To conduct the study, the team combined retinal scans, genetic data, and blood sample analyses from over 74,000 participants.

People with simpler, less branched blood vessels were found to be at increased risk of cardiovascular diseases and showed signs of biological ageing, such as higher inflammation and shorter lifespan.

Currently, assessing age-related diseases like heart disease, stroke, and dementia requires multiple tests. The hope is that retinal scans alone could eventually be used as a quick, accessible way to assess ageing and cardiovascular risk. However, more research is needed.

The team also reviewed blood biomarkers and genetic data and identified potential biological causes behind changes in the eye's blood vessels. This helped them identify specific proteins that may drive ageing and disease -- MMP12 and IgG-Fc receptor IIb.

Both proteins are linked to inflammation and vascular ageing. According to Pigeyre, these proteins could be potential targets for future drugs."Our findings point to potential drug targets for slowing vascular ageing, reducing the burden of cardiovascular diseases, and ultimately improving lifespan," she said. Study shows eye scans may provide clues to ageing, heart disease risk | MorungExpress | morungexpress.com
Read More........

Rapid BP fluctuations may signal risk of brain degeneration in elderly

(Photo: AI generated image/IANS)

New Delhi, (IANS) Older adults whose blood pressure fluctuates widely may indicate a greater risk of brain shrinkage and nerve cell injury, according to a new study.

The study, published in the Journal of Alzheimer’s Disease, reveals that short-term “dynamic instability” in blood pressure -- moment-to-moment changes measured over just minutes -- is linked to loss of brain tissue in regions critical for memory and cognition, as well as to blood biomarkers of nerve cell damage.

“Our findings show that even when average blood pressure is normal, instability from one heartbeat to the next may place stress on the brain,” said Daniel Nation, from the University of Southern California’s Leonard Davis School of Gerontology.

“These moment-to-moment swings appear to be associated with the same kinds of brain changes we see in early neurodegeneration,” added the Professor of Gerontology and Medicine.

While high average blood pressure has long been known to increase the risk of dementia, this study focuses on blood pressure variability, or how much blood pressure rises and falls over short time periods.

Recent evidence suggests that such fluctuations can strain small blood vessels in the brain and reduce their ability to deliver steady blood flow.

In this study, the researchers combined two complementary measures: Average Real Variability (ARV) and Arterial Stiffness Index (ASI).

ARV captures how much systolic blood pressure (the top number in a blood pressure reading) changes between each heartbeat, while ASI reflects how flexible or stiff the arteries are as they respond to those changes in pressure.

Together, these measures indicate how much blood flow changes over a short period of time, or what the researchers call “blood pressure dynamic instability.”

"This study suggests that excessive fluctuations could be a sign of vascular ageing that contributes to brain injury,” Nation explained.

The team conducted MRI scans of 105 community-dwelling older adults between the ages of 55 and 89 who were generally healthy and had no major neurological disease.

Participants with both high ARV and high ASI were found to have smaller hippocampal and entorhinal cortex volumes -- brain regions vital for learning and memory, also the first affected by Alzheimer’s disease.

Blood samples showed that the same individuals also had higher levels of neurofilament light (NfL), a blood-based marker that rises when nerve cells are damaged.The findings open a new window into how cardiovascular changes contribute to cognitive decline and may offer novel prevention strategies. Rapid BP fluctuations may signal risk of brain degeneration in elderly | MorungExpress | morungexpress.com
Read More........

A Combination Implant and Augmented Reality Glasses Restores Reading Vision to Blind Eyes

Study participant Sheila Irvine training with the device – credit Moorfields Eye Hospital

A “new era” has begun in the development of artificial vision after a combination electronic eye implant—with augmented reality glasses restored vision to blind eyes in patients with untreatable macular degeneration.

Those treated with the device could read, on average, five lines of a vision chart, even though some could not even see the chart before their surgery.

The results of the European clinical trial which involved 38 patients in 17 hospitals across 5 countries were published in The New England Journal of Medicine. They showed 84% of participants were able to read letters, numbers, and words using prosthetic vision through an eye that had previously lost its sight due to the untreatable progressive eye condition, “geographic atrophy with dry age-related macular degeneration (GA in dry AMD).”

The now-proven device is called PRIMA, and consists of an ultra-thin microchip implanted in the eye that receives infrared projections of the waking world by a video camera installed in a pair of augmented reality classes.

A pocket computer fixed to a small control panel worn on the waistband then runs artificial intelligence algorithms to process the information contained in the infrared projection, which is converted into an electrical signal. This signal passes through the retinal and optical nerve cells into the brain, where it’s interpreted as vision.

The patient uses their glasses to focus and scan across the main object in the projected image from the video camera, using the zoom feature to enlarge the text. Each patient goes through an intensive rehabilitation program over several months to learn to interpret these signals and start reading again.

“In the history of artificial vision, this represents a new era,” said Mr. Mahi Muqit, associate professor at the UK’s University College London’s Institute of Ophthalmology and consultant at Moorfields Eye Hospital where the UK arm of the trial was conducted.

“Blind patients are actually able to have meaningful central vision restoration, which has never been done before.”

“Getting back the ability to read is a major improvement in their quality of life, lifts their mood and helps to restore their confidence and independence. The PRIMA chip operation can safely be performed by any trained vitreoretinal surgeon in under two hours—that is key for allowing all blind patients to have access to this new medical therapy for GA in dry AMD.”

Dry AMD is a slow deterioration of the cells of the macula over many years, as the light-sensitive retinal cells die off. For most people with dry AMD, they can experience a slight loss of central vision.

Through a process known as geographic atrophy (GA), it can progress to full vision loss in the eye, as the cells die and the central macula melts away. There is currently no treatment for GA, which affects 5 million people globally. All participants in this trial had lost the central sight of the eye being tested, leaving only limited peripheral vision.

Scans of the implant in a patient’s eye – credit Science Corporation

The procedure in install the implant involves a vitrectomy, where the eye’s vitreous jelly is removed from between the lens and the retina, and the surgeon inserts the ultra-thin microchip, which is shaped like a SIM card and just 2mm x 2mm.

The PRIMA System device used in this operation is being developed by Science Corporation, which develops brain-computer interfaces and neural engineering. No significant decline in existing peripheral vison was observed in trial participants, and these findings pave the way for seeking approval to market this new device.

UCL spoke with one of the patients who received the implant for the college’s news outlet.

“I wanted to take part in research to help future generations, and my optician suggested I get in touch with Moorfields,” began Sheila Irvine, one of Moorfields’ patients on the trial. “Before receiving the implant, it was like having two black discs in my eyes, with the outside distorted.

“I was an avid bookworm, and I wanted that back. I was nervous, excited, all those things. There was no pain during the operation, but you’re still aware of what’s happening. It’s a new way of looking through your eyes, and it was dead exciting when I began seeing a letter. It’s not simple, learning to read again, but the more hours I put in, the more I pick up.”

“The team at Moorfields has given me challenges, like ‘Look at your prescription,’ which is always tiny. I like stretching myself, trying to look at the little writing on tins, doing crosswords.”

The global trial was led by Dr. Frank Holz of the University of Bonn, with participants from the UK, France, Italy, and the Netherlands.

Mr. Muqit that it left him feeling that a door was opened for medical devices in this area, because there is no treatment currently licensed for dry AMD.“I think it’s something that, in future, could be used to treat multiple eye conditions.” A Combination Implant and Augmented Reality Glasses Restores Reading Vision to Blind Eyes
Read More........

First Antidote for Carbon Monoxide Poisoning 'Cleans' Blood in Minutes

A plug-in carbon monoxide detector – credit Fastily CC 4.0. BY-SA

It’s invisible, it’s lethal, and it’s been with us for decades, but carbon monoxide poisoning can now be fought with the first-ever antidote that rapidly removes the toxic molecule from the bloodstream.

Carbon monoxide or CO, poisoning accounts for 50,000 emergency room visits in the US each year and causes about 1,500 deaths, each one being lamented as a shameful waste and tragic oversight.

Currently, the only treatments for CO poisoning are oxygen-based therapies, which help the body eliminate the toxic gas. However, even with treatment, nearly half of survivors suffer long-term heart and brain damage. This has created an urgent need for faster, more effective interventions.

In a study published by University of Maryland School of Medicine (UMSOM) in PNAS, the research team developed a new engineered protein-based therapy called RcoM-HBD-CCC, which acts like a sponge to soak up carbon monoxide from the blood.

RcoM (short for “regulator of metabolism”) is a natural protein isolated from the bacterium Paraburkholderia xenovorans which uses it to sense minute levels of carbon monoxide in its environment.

The researchers engineered a version that is highly selective, grabbing CO without interfering with oxygen or other important molecules in the bloodstream like nitric oxide, which is vital for the regulation of blood pressure.

In tests on mice, the new therapy worked quickly to remove CO from red blood cells and was safely flushed out of the body through urine.

CO is known commonly as the “silent killer,” because this odorless, invisible gas, typically released from combustion sources, including stovetops, propane heaters, car exhausts, and firewood, poisons in a gradual manner that isn’t immediately obvious to the victim.

In healthy bodies, oxygen inhaled from the air binds to the protein hemoglobin on the surface of red blood cells, which then ferry the oxygen to all the tissues of the body. CO however, competes with oxygen for hemoglobin. It enters the bloodstream and binds to hemoglobin with a 200 to 400-fold greater affinity than oxygen. That means CO hogs most of the hemoglobin seats, so not enough oxygen molecules can get a ride to the tissues that need them.

Currently, the only available treatments for carbon monoxide poisoning involve giving 100% pure oxygen, sometimes under pressure in a hyperbaric chamber.

All too often, patients are not transported, diagnosed, and treated in time to reverse the effects of CO poisoning, which can cause lasting cardiac and neurological injuries or even death.

Infused in the bloodstream, scavenger hemoproteins like RcoM-HBD-CCC rapidly bind to carbon monoxide molecules, reducing the time it takes to clear half of the carbon monoxide in the blood to less than a minute, compared to more than hour with pure oxygen therapy and five hours without any treatment.

A potential drawback the researchers were aware of is that so-called “scavengers” like RcoM also have an affinity for oxygen, and so may uptake the nitric oxide mentioned earlier. This can cause wild and potentially unsafe changes in blood pressure, but RcoM-HBD-CCC caused no such side effects.

“Unlike other protein-based treatments, we found the compound caused only minimal changes in blood pressure, which was an exciting finding and raised the potential for this new molecule to have clinical applications,” said study corresponding author Mark T. Gladwin, MD, Dean of UMSOM.

“This has the potential to become a rapid, intravenous antidote for carbon monoxide that could be given in the emergency department or even in the field by first-responders.”Future studies will likely include more pre-clinical research to determine the safe and effective dosage range for RcoM-HBD-CCC in treating carbon monoxide poisoning. It could also form the basis for new research in other fields, including as an oxygen delivery therapy or blood substitute. This could include hemorrhagic shock, acute respiratory distress syndrome (ARDS), severe anemias, and the preservation of organs for transplantation. First Antidote for Carbon Monoxide Poisoning 'Cleans' Blood in Minutes
Read More........

Poor sleep may make your brain age faster – new study

Abigail Dove, Karolinska Institutet

We spend nearly a third of our lives asleep, yet sleep is anything but wasted time. Far from being passive downtime, it is an active and essential process that helps restore the body and protect the brain. When sleep is disrupted, the brain feels the consequences – sometimes in subtle ways that accumulate over years.

In a new study, my colleagues and I examined sleep behaviour and detailed brain MRI scan data in more than 27,000 UK adults between the ages of 40 and 70. We found that people with poor sleep had brains that appeared significantly older than expected based on their actual age.

What does it mean for the brain to “look older”? While we all grow chronologically older at the same pace, some people’s biological clocks can tick faster or slower than others. New advances in brain imaging and artificial intelligence allow researchers to estimate a person’s brain age based on patterns in brain MRI scans, such as loss of brain tissue, thinning of the cortex and damage to blood vessels.

In our study, brain age was estimated using over 1,000 different imaging markers from MRI scans. We first trained a machine learning model on the scans of the healthiest participants – people with no major diseases, whose brains should closely match their chronological age. Once the model “learned” what normal ageing looks like, we applied it to the full study population.

Having a brain age higher than your actual age can be a signal of departure from healthy ageing. Previous research has linked an older-appearing brain to faster cognitive decline, greater dementia risk and even higher risk of early death.

Sleep is complex, and no single measure can tell the whole story of a person’s sleep health. Our study, therefore, focused on five aspects of sleep self-reported by the study participants: their chronotype (“morning” or “evening” person), how many hours they typically sleep (seven to eight hours is considered optimal), whether they experience insomnia, whether they snore and whether they feel excessively sleepy during the day.

These characteristics can interact in synergistic ways. For example, someone with frequent insomnia may also feel more daytime sleepiness, and having a late chronotype may lead to shorter sleep duration. By integrating all five characteristics into a “healthy sleep score”, we captured a fuller picture of overall sleep health.

People with four or five healthy traits had a “healthy” sleep profile, while those with two to three had an “intermediate” profile, and those with zero or one had a “poor” profile.

When we compared brain age across different sleep profiles, the differences were clear. The gap between brain age and chronological age widened by about six months for every one point decrease in healthy sleep score. On average, people with a poor sleep profile had brains that appeared nearly one year older than expected based on their chronological age, while those with a healthy sleep profile showed no such gap.

We also considered the five sleep characteristics individually: late chronotype and abnormal sleep duration stood out as the biggest contributors to faster brain ageing.

A year may not sound like much, but in terms of brain health, it matters. Even small accelerations in brain ageing can compound over time, potentially increasing the risk of cognitive impairment, dementia and other neurological conditions.

The good news is that sleep habits are modifiable. While not all sleep problems are easily fixed, simple strategies: keeping a regular sleep schedule; limiting caffeine, alcohol and screen use before bedtime; and creating a dark and quiet sleep environment can improve sleep health and may protect brain health.

How exactly does the quality of a person’s sleep affect their brain health?

One explanation may be inflammation. Increasing evidence suggests that sleep disturbances raise the level of inflammation in the body. In turn, inflammation can harm the brain in several ways: damaging blood vessels, triggering the buildup of toxic proteins and speeding up brain cell death.

We were able to investigate the role of inflammation thanks to blood samples collected from participants at the beginning of the study. These samples contain a wealth of information about different inflammatory biomarkers circulating in the body. When we factored this into our analysis, we found that inflammation levels accounted for about 10% of the connection between sleep and brain ageing.

Other processes may also play a role

Another explanation centres on the glymphatic system – the brain’s built-in waste clearance network, which is mainly active during sleep. When sleep is disrupted or insufficient, this system may not function properly, allowing harmful substances to build up in the brain.

Yet another possibility is that poor sleep increases the risk of other health conditions that are themselves damaging for brain health, including type 2 diabetes, obesity and cardiovascular disease.

Our study is one of the largest and most comprehensive of its kind, benefiting from a very large study population, a multidimensional measure of sleep health, and a detailed estimation of brain age through thousands of brain MRI features. Though previous research connected poor sleep to cognitive decline and dementia, our study further demonstrated that poor sleep is tied to a measurably older-looking brain, and inflammation might explain this link.

Brain ageing cannot be avoided, but our behaviour and lifestyle choices can shape how it unfolds. The implications of our research are clear: to keep the brain healthier for longer, it is important to make sleep a priority.The Conversation

Abigail Dove, Postdoctoral Researcher, Neuroepidemiology, Karolinska Institutet

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Read More........

The Subtle Power of Unhearable Sound: Mood and Cognition-Altering Agents

For representational purpose (Image by Gerd Altmann from Pixabay)

Shreyas Kannan, Plaksha University: The human ear has a maximum hearing range of 20 Hz to 20,000 Hz. However, in all reality the range at which we are most sensitive is from 1000 Hz to 4000 Hz at which most natural speech occurs. As frequency decreases, the sound energy or decibels needed to hear sounds increases, which makes the sound effectively “too soft” unless played at a high enough volume. What this means is that the lower and higher frequencies are both difficult to perceive normally, and frequencies outside of this range entirely, Infrasound, which vibrates below 20 Hz, and ultrasound, which is above 20,000 Hz, are simply imperceptible.

These imperceptible sounds however, have a very perceptible effect. Vic Tandy, a British engineer, believed his laboratory was haunted—until he discovered that a silent 19 Hz sound wave, produced by a fan, was resonating with his eyeballs and triggering shadowy hallucinations. Even though these sounds were below the threshold of human hearing, it could still alter mood, physiology, and cognition.

Infrasound and ultrasound can also have indirect subliminal effects. They can very subtly and over long durations of time have a negative or positive effect on the psyche of the listener. Infrasound, although inaudible, can cause a range of adverse effects, including fatigue, sleep disturbance, and cognitive dysfunction.

How does this work, especially for sounds we can’t even hear? The sounds in the Ultrasonic range tend to stimulate the emotional centers of the brain, which generally are the amygdala and hippocampus, to name a few. A study proceeded to track this and found that sounds containing inaudible high-frequency components induced activation in deep brain structures associated with emotion and reward. This effectively demonstrates a reflexive unconscious emotional response, be it positive or negative, toward a specific band of sound frequencies.

The issues do not end here. There is a persistent worry of chronic exposure to just basic sound, not just ultrasonic or infrasonic sound, having long term effects on the brain. Symptoms such as ‘chronic fatigue,’ ‘repeated headache,’ and ‘backache’ are observed to be highly associated with low- and mid-octave band center frequency noise exposure among the sampled workers. Among the major psychological symptoms... It is evident that ‘irritability’ is highly associated with low- and mid-octave band noise frequency characteristics. In conclusion even when the noise isn't painfully loud, its frequency can still degrade physical and mental health over time which should be raising ethical and public health concerns.

These effects, as can be surmised, are highly weaponizable “smart consumer devices produce possibly imperceptible sound at both high (17–21kHz) and low (60–100Hz) frequencies, at the maximum available volume setting, potentially turning them into acoustic cyber-weapons.”

The physical and systemic effects that can be caused by long exposure to something that can technically originate from our devices, especially considering previously what the Infrasonic and ultrasonic bands can potentially do. Overall, we find that many of the devices tested are capable of reproducing frequencies within both high and low ranges, at levels exceeding those recommended in published guidelines. Such attacks are often trivial to develop and, in many cases, could be added to existing malware payloads, as they may be attractive to adversaries with specific motivations or targets.

One particular patent actually claims that 1/2 Hz frequency (Around 0.5 Hz) affects the autonomic nervous system and can produce a variety of effects, not limited to Eyelid drooping (ptosis) Relaxation and drowsiness Feeling of pressure on the forehead Visual effects with eyes closed Stomach sensations Tenseness (at certain frequencies). It goes on to propose how this can be used in law enforcement in the form of Non-lethal crowd control Creating disorientation in standoff situations and Remote manipulation from a distance. It goes on to list the effects of the 2.5 Hz range and the other set of effects this has.

However, not all sound effects are bad. Certain ways of application of sound can be used to actually help treat mental issues. One example is through the use of binaural beats, a form of imperceptible or subtle auditory stimulation, which are being studied for their effects on mood regulation, anxiety, and depression. Binaural beats are a type of sound that can influence brainwave activity by playing two slightly different frequencies in each ear, creating a perceived third “beat” in the brain in the way of a non-invasive sound-based intervention. A systematic study conducted to this end found positive effects in the short term while stressing that further research was needed in the long term to determine the full scope of positive effects.

It should also be noted that while these frequencies can be used negatively, it is perfectly possible for them to be used positively. Playing the right type of sound, be it music or a particular frequency set at a volume too low to be heard tended to elicit a positive response on mood and well being.

From the different sources of literature and patent claims, it can be surmised that with the exact know-how and mapping of which exact frequency to use to affect a person in a certain manner, one could be completely manipulated to actually feel a certain way about a topic that we might actually dislike. Any emotion can be aroused as necessary. Furthermore, it can be done through the speakers in everyday devices! An advertisement for a product could play the right sounds to make you view it more favourably, documentaries could potentially use this to make you feel particularly worse about a certain topic to increase the impact, electoral candidates can subtly change their image playing the right sounds at the right time, interviewees could potentially be influenced to feel uneasy for no ‘explainable’ reason as a form of sabotage, etc! The actual potential for abuse of the sounds we cannot even hear, is extreme.

How can we protect ourselves from these phenomena? The answer is quite difficult, especially at this age where sounds come from everywhere around us. The solution to this is to call for scientific transparency, proper protocols to monitor the actual playing sounds and strictly maintaining awareness of one's surroundings. In this day and age we must learn to listen to sounds that we cannot hear.Shreyas Kannan is a B.Tech student in Robotics and Cyber-Physical Systems (RCPS) at Plaksha University, and part of its inaugural graduating batch. He has an ardent passion for all things related to movement and propulsion in vehicles, and brings boundless curiosity and energy to projects that make objects move—whether on land, underwater, or in space. From autonomous underwater navigation to aerospace systems, Shreyas is eager to explore and contribute to the frontier of motion-driven technologies. The Subtle Power of Unhearable Sound: Mood and Cognition-Altering Agents | MorungExpress | morungexpress.com
Read More........

Indian researchers develop diagnostic device to detect early-stage bone cancer



New Delhi, (IANS) In a major scientific breakthrough, researchers from IIT (BHU) in Uttar Pradesh have developed a miniaturised, self-reporting diagnostic device that can detect early-stage bone cancer with high precision.

The first-of-its-kind sensor detects osteopontin (OPN) -- a key biomarker for bone cancer.

The device is reagent-free, portable, and cost-effective and is ideal for rural healthcare, said the research team led by Dr. Pranjal Chandra from the School of Biochemical Engineering.

The device works much like a glucose metre and enables quick, accurate, and on-the-spot detection, even in resource-limited settings.

The device uses a custom sensor surface composed of gold and redox-active nanomaterials, allowing it to function similarly to a glucose meter.

“This technology simplifies cancer detection and empowers primary health centres,” said Prof. Chandra. The findings are published in the prestigious journal Nanoscale (Royal Society of Chemistry, UK).

OPN is a crucial biomarker associated with osteosarcoma -- a highly aggressive form of bone cancer that primarily affects children and adolescents.

While current methods to detect OPN are costly and time-consuming, the new device offers rapid and accurate results with minimal equipment.

It is designed as a reagent-less immunosensor, which enables on-the-spot and affordable testing. It is especially beneficial in rural and resource-constrained areas where early cancer detection is often delayed.

Cancer is a major public health concern in India, with rising incidence rates and significant mortality.

Lauding the innovation, Director Prof. Amit Patra called it “a prime example of technology with a human face”. He said it contributes to precision medicine and national health priorities. He added that the innovation aligns with the government's Make in India and Start-up India initiatives.A patent application has been filed, and efforts are underway to convert the prototype into a smartphone-compatible diagnostic kit for remote healthcare access, the researchers said. Indian researchers develop diagnostic device to detect early-stage bone cancer | MorungExpress | morungexpress.com
Read More........

Scientists Regrow Retina Cells to Tackle Leading Cause of Blindness Using Nanotechnology


Macular degeneration is the leading cause of blindness in developed countries, but regrowing the human cells lost to this condition was the feature of a new successful treatment that took advantage of advances in nanotechnology.

Regrowing the cells of the human retina on a scaffold of synthetic, tissue-like material showed substantial improvements over previously used materials such as cellulose, and the scientists hope they can move on to testing their method in the already blind.

Macular degeneration is increasing in prevalence in the developed world. It’s the leading cause of blindness and is caused by the loss of cells in a key part of the eye called the retina.

Humans have no ability to regrow retinal pigment cells, but scientists have determined how to do it in vitro using pluripotent stem cells. However as the study authors describe, previous examples of this procedure saw scientists growing the cells on flat surfaces rather than one resembling the retinal membrane.

This, they state, limits the effectiveness of transplanted cells.

In a study at the UK’s Nottingham Trent University, biomedical scientist Biola Egbowon and colleagues fabricated 3D scaffolds with polymer nanofibers and coated them with a steroid to reduce inflammation.

The method by which the nanofibers were made was pretty darn cool. The team would squirt polyacrylonitrile and Jeffamine polymers in molten form through an electrical current in a technique known as “electrospinning.” The high voltage caused molecular changes in the polymers that saw them become solid again, resembling a scaffold of tiny fibers that attracted water yet maintained mechanical strength.

After the scaffolding was made, it was treated with an anti-inflammatory steroid.

This unique pairing of materials mixed with the electrospinning created a unique scaffold that kept the retinal pigment cells viable for 150 days outside of any potential human patient, all while showing the phenotype of biomarkers critical for maintaining retinal physiological characteristics.“While this may indicate the potential of such cellularized scaffolds in regenerative medicine, it does not address the question of biocompatibility with human tissue,” Egbowon and colleagues caution in their paper, urging more research to be conducted, specifically regarding the orientation of the cells and whether they can maintain good blood supply. Scientists Regrow Retina Cells to Tackle Leading Cause of Blindness Using Nanotechnology
Read More........

Gene essential for vitamin D absorption may boost cancer treatment

IANS Photo

New Delhi, (IANS): Scientists have identified a key gene essential for vitamin D absorption, which may also boost treatments for cancer and autoimmune diseases.

The gene, called SDR42E1, is crucial for taking up vitamin D from the gut and further metabolising it -- a discovery with many possible applications in precision medicine, including cancer therapy.

"Here we show that blocking or inhibiting SDR42E1 may selectively stop the growth of cancer cells,” said Dr Georges Nemer, Professor at the University of College of Health and Life Sciences at Hamad Bin Khalifa University in Qatar.

Previous research showed that a specific mutation in the SDR42E1 gene on chromosome 16 is associated with vitamin D deficiency.

The mutation caused the protein to be cut short, rendering it inactive.

In the study, published in the journal Frontiers in Endocrinology, the researchers used CRISPR/Cas9 gene editing to transform the active form of SDR42E1 in a line of cells from a patient with colorectal cancer, called HCT116, into its inactive form.

In HCT116 cells, the expression of SDR42E1 is usually abundant, suggesting that the protein is essential for their survival.

Once the faulty SDR42E1 copy had been introduced, the viability of the cancer cells plummeted by 53 per cent, the researchers explained.

The results suggest that inhibiting the gene can selectively kill cancer cells, while leaving neighbouring cells unharmed.

“Our results open new potential avenues in precision oncology, though clinical translation still requires considerable validation and long-term development," said Dr Nagham Nafiz Hendi, Professor at Middle East University in Amman, Jordan.

“Because SDR42E1 is involved in vitamin D metabolism, we could also target it in any of the many diseases where vitamin D plays a regulatory role,” said Nemer.However, as long-term effects of SDR42E1 on vitamin D balance remain to be fully understood, the researchers stressed the need for further studies. Gene essential for vitamin D absorption may boost cancer treatment | MorungExpress | morungexpress.com
Read More........

US scientists developing single-dose vaccines for HIV, Covid


New Delhi, August 28 (IANS) A team of scientists in the US is working to develop vaccines that can protect against HIV, Covid, and potentially other diseases, with a single dose.

The team from MIT and the Scripps Research Institute treated mice with a vaccine that combines two different adjuvants, materials that help stimulate the immune system. They found that the combination helped generate more robust immune responses.

The dual-adjuvant vaccine was found to accumulate in the lymph nodes, where white blood cells known as B cells encounter antigens and undergo rapid mutations that generate new antibodies.

The vaccine’s antigens remained there for up to a month -- allowing the immune system to build up a much greater number and diversity of antibodies against the HIV protein than the vaccine given alone or with one adjuvant.

According to MIT professor J. Christopher Love, the approach may mimic what occurs during a natural infection and could lead to an immune response so strong and broad that vaccines only need to be given once.

“It offers the opportunity to engineer new formulations for these types of vaccines across a wide range of different diseases, such as influenza, SARS-CoV-2, or other pandemic outbreaks,” Love said.

Separately, Russia’s Covid-19 vaccine maker is also set to develop an mRNA-based HIV vaccine, RIA Novosti, the Russian Information Agency, said.

The vaccine to be developed by Gamaleya Center in Moscow, which will trigger an immune response against the AIDS causing virus, could be ready in around two years.

The much-anticipated HIV vaccine is based on mRNA technology, the head of the institute’s epidemiology department, Vladimir Gushchin, told RIA Novosti on Wednesday.

“We are currently at the stage of creating the first antigens that will generate a broadly neutralising immune response. The success of the vaccine will depend on whether the immunogen we use can trigger a response capable of protecting against all variants,” said Vladimir Gushchin, epidemiologist at the Centre.The Gamaleya Center also developed Sputnik V, one of the world’s first Covid-19 vaccines, which was rolled out in August 2020. The shot, showing up to 97.8 per cent efficacy with no serious side effects, has been approved in nearly 70 countries. US scientists developing single-dose vaccines for HIV, Covid | MorungExpress | morungexpress.com
Read More........